Company: CCIXW
Filing Date: 2025-12-05
Form Type: S-4/A
Source: 0001193125-25-309933
Chunk: 61

Company: Churchill Capital Corp IX/Cayman
Filing Date: 2025-12-05
Form: S-4/A
Chunk 61
---
 Company is calculated as the quotient of (1) (a) the amount of funds held in the trust account (under each of the scenarios presented above), less (b) the amount of estimated CCIX transaction expenses of $25.0 million, divided by (2) the number of CCIX Class A Ordinary Shares anticipated to be outstanding as of immediately prior to the Closing (assumed to be 36,662,500 shares under the No Redemption Scenario, 29,475,000 under the 25% Redemption Scenario, 22,287,500 under the 50% Redemption Scenario, and 10,707,876 shares under the Maximum Redemption Scenario). The estimated net cash per share of CCIX shares that is being contributed to the Post-Closing Company (under each of the scenarios presented above) is less than the $10.00 per share ascribed to such shares in the Merger Agreement or the amount per share that holders of CCIX’s public shares would be entitled to receive upon exercise of their redemption rights (which, for illustrative purposes, was approximately $10.59 per share as of September 30, 2025, the CCIX record date). Q. Will CCIX or PlusAI obtain new financing in connection with the business combination? A. As of the date hereof, neither CCIX nor PlusAI have executed agreements with respect to new financing in connection with the business combination that are not otherwise disclosed herein. The impact of all currently anticipated sources of financing is reflected in the pro forma financial statements and other pro forma disclosure throughout this proxy statement/prospectus. There are no limitations on CCIX’s ability to obtain new financing in connection with the business combination, except those arising under Cayman law, CCIX’s governing documents and Nasdaq rules.

<div align='center'>20</div>

PlusAI’s ability to pursue one or more Permitted Equity Financings after the date of the Merger Agreement is subject to the following limitations contained in the Merger Agreement: (1) except for financing raised under a previously agreed form of PlusAI Safe, CCIX consent (not to be unreasonably withheld, conditioned or delayed) is required; (2) the aggregate number of securities issued or issuable by the PlusAI in connection with all Permitted Equity Financings may not result in a change in control of PlusAI; (3) no Permitted Equity Financing may alter the terms of the Merger Agreement or the related transaction agreements or delay or impair the business combination; (